| Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates |
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-05-12 22:10:45 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results |
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2025, and provided an update on recent business achievements. |
globenewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September |
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis (gMG). |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Participate in Two Upcoming Investor Events |
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events. |
globenewswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? |
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-03 15:05:38 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates |
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. |
zacks.com |
2025-03-11 20:10:20 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results |
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements. |
globenewswire.com |
2025-03-11 18:01:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors |
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion |
globenewswire.com |
2025-03-05 09:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences |
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences: |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences |
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. |
globenewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates |
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago. |
zacks.com |
2024-11-07 20:36:50 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results |
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24 |
globenewswire.com |
2024-11-07 18:01:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences |
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: |
globenewswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting |
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia. |
globenewswire.com |
2024-10-15 11:00:00 |
Czytaj oryginał (ang.) |
| Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? |
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2024-10-09 08:50:15 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates |
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago. |
zacks.com |
2024-08-08 22:25:29 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results |
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H'24 Approximately $361 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2024, and provided an update on recent business achievements. |
globenewswire.com |
2024-08-08 20:01:00 |
Czytaj oryginał (ang.) |
| Dianthus (DNTH) Gains 18% in the Past Month: Here's Why |
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026. |
zacks.com |
2024-07-08 16:11:08 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) |
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki. |
globenewswire.com |
2024-06-28 15:30:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) |
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q'24 and planned initiation of a Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 2H'24 Recently disclosed head-to-head affinity and PD potency data reinforce DNTH103 is a highly potent, potential best-in-class active C1s inhibitor designed for self-administration in a low-volume, subcutaneous autoinjector once every two weeks NEW YORK and WALTHAM, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of its Phase 2 Investigational New Drug (IND) application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy (MMN). |
globenewswire.com |
2024-06-12 11:00:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference |
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York. |
globenewswire.com |
2024-05-30 20:30:00 |
Czytaj oryginał (ang.) |
| Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH) |
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – HC Wainwright issued their Q2 2024 EPS estimates for Dianthus Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.16) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q3 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.65) EPS, Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($3.82) EPS, FY2027 earnings at ($4.30) EPS and FY2028 earnings at ($3.26) EPS. Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.73 million. Several other equities research analysts also recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 price objective for the company. Jefferies Financial Group lifted their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Raymond James lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Finally, Wedbush boosted their target price on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $42.83. Get Our Latest Report on Dianthus Therapeutics Dianthus Therapeutics Trading Down 2.4 % NASDAQ DNTH opened at $25.63 on Monday. The firm’s fifty day simple moving average is $25.63 and its two-hundred day simple moving average is $18.97. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77. The firm has a market capitalization of $752.21 million, a P/E ratio of -4.40 and a beta of 1.77. Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new position in Dianthus Therapeutics in the fourth quarter valued at $25,000. Citigroup Inc. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $53,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth about $630,000. Acadian Asset Management LLC purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $303,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $497,000. Hedge funds and other institutional investors own 47.53% of the company’s stock. Dianthus Therapeutics Company Profile (Get Free Report) Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. See Also Five stocks we like better than Dianthus Therapeutics Retail Stocks Investing, Explained MarketBeat Week in Review – 5/13 – 5/17 Why Invest in Biotech Stocks Take-Two Interactive Software Offers 2nd Chance for Investors 3 Grocery Stocks That Can Help Take a Bite Out of Inflation Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:38:50 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results |
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H'25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor Neuropathy (MMN) to initiate 2Q'24 and Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H'24 $377 million of cash, including proceeds from a successful $230 million PIPE financing completed in January 2024, provides runway into 2H 2027 NEW YORK and WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements. |
globenewswire.com |
2024-05-09 20:01:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference |
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Bank of America Securities 2024 Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Tuesday, May 14, 2024 at 4:20 p.m. PT in Las Vegas. |
globenewswire.com |
2024-05-08 20:30:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on May 1, 2024, to two newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-05-03 20:30:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting |
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually. |
globenewswire.com |
2024-04-11 11:30:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-04-05 20:30:00 |
Czytaj oryginał (ang.) |
| Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks |
Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward. |
zacks.com |
2024-03-26 12:46:08 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results |
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1'24 with top-line results anticipated in 2H'25 |
globenewswire.com |
2024-03-21 18:01:00 |
Czytaj oryginał (ang.) |
| Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-03-07 18:30:00 |
Czytaj oryginał (ang.) |